RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that it will be presenting at the RHK Capital 2019 Disruptive Growth & Healthcare Conference (www.disruptnyc.com). RHK Capital’s Disruptive Growth & Healthcare Conference showcases life science companies that focus on solutions for unmet …
Helix BioPharma Crop. Submits L-DOS47 IND Application with U.S. FDA For Pancreatic Cancer
RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the submission of an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for approval to initiate a Phase I/II clinical study protocol with L-DOS47, to be given …
Helix BioPharma Corp. Announces Fiscal Third Quarter 2019 Results
(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces its financial results for its fiscal third quarter ended April 30, 2019.
Helix BioPharma Corp. Initiates OTCQB Application and Hires U.S. Investor Relations Firm
RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announced that it has commenced the process to have the Company’s common shares quoted on the OTCQB® Market exchange in the United States. The Company’s U.S. legal counsel, Sheppard Mullin, Richter and Hampton LLC …
Helix BioPharma Corp. Closes Private Placement
(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of CAD507,960.
L-DOS47 Phase II Randomized Study Advances to Second Cohort
RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, has announced that the Trial Steering Committee (“TSC”) reviewed safety data from the first dosing cohort of the Company’s LDOS003 study. No serious adverse events or dose limiting toxicities were observed. TSC recommended that …
Helix BioPharma Corp. Closes Second Tranche of Private Placement
(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a second tranche of a private placement financing for gross proceeds of CAD510,000. The Company is working on completing another private placement financing tranche by May 17, 2019.
Helix BioPharma Corp. Retains U.S. Legal and Capital Firms to Advise on U.S. Listing
(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has retained Sheppard Mullin, Richter and Hampton LLC (“Sheppard Mullin”) and RHK Capital (“RHK”). Sheppard Mullin will advise the Company on U.S. general corporate matters and securities law as the …
Helix BioPharma Corp. Reports Voting Results
(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the voting results of the Company’s annual and special meeting of shareholders held on April 15, 2019 (the “Meeting”).
Helix BioPharma Corp. Announces Fiscal Second Quarter 2019 Results
(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces its financial results for its fiscal second quarter ended January 31, 2019.